- Can-Fite: Presenting Namodenoson’s New Pancreatic Cancer Indication to Potential Partners at BioEquity Europe 2023
- Can-Fite to Initiate Exploratory Phase 2 Trial with Namodenoson in Pancreatic Cancer Patients
- Inhibition of Pancreatic Cancer by Namodenoson: Molecular Mechanism of Action Discovered by Can-Fite Scientists
- Can-Fite Announces New Management Structure as Advanced Stage Pipeline Moves Toward Commercialization
- Can-Fite: EMA Gives Green Light for Piclidenoson Pivotal Phase III Clinical Trial for Psoriasis Treatment
- Can-Fite Reports 2022 Financial Results & Provides Clinical Update
- Can-Fite to Conduct Meetings at the BIO-Europe Spring Conference with Pharma Companies Interested in Licensing and Distributing Piclidenoson and Namodenoson
- Can-Fite to Treat Decompensated Liver Cirrhosis Patients with Namodenoson Under Compassionate Use Setting
As of last trade
Can Fite Biopharma Ltd (CF5:STU) traded at 5.05, 3.06% above its 52-week low of 4.90, set on Jan 06, 2023.
4.90Jan 06 202310.20Jun 29 2022
Data delayed at least 15 minutes, as of Jan 06 2023.